Tenax Therapeutics (TENX) Competitors $6.42 +0.17 (+2.64%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TENX vs. VTGN, TCRX, ONCY, HLVX, COYA, SRZN, SAVA, ADAG, KALA, and ATOSShould you be buying Tenax Therapeutics stock or one of its competitors? The main competitors of Tenax Therapeutics include VistaGen Therapeutics (VTGN), TScan Therapeutics (TCRX), Oncolytics Biotech (ONCY), HilleVax (HLVX), Coya Therapeutics (COYA), Surrozen (SRZN), Cassava Sciences (SAVA), Adagene (ADAG), KALA BIO (KALA), and Atossa Genetics (ATOS). These companies are all part of the "pharmaceutical products" industry. Tenax Therapeutics vs. Its Competitors VistaGen Therapeutics TScan Therapeutics Oncolytics Biotech HilleVax Coya Therapeutics Surrozen Cassava Sciences Adagene KALA BIO Atossa Genetics Tenax Therapeutics (NASDAQ:TENX) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation. Do analysts recommend TENX or VTGN? Tenax Therapeutics currently has a consensus price target of $18.00, suggesting a potential upside of 180.81%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenax Therapeutics is more favorable than VistaGen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20VistaGen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor TENX or VTGN? In the previous week, Tenax Therapeutics had 3 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 4 mentions for Tenax Therapeutics and 1 mentions for VistaGen Therapeutics. Tenax Therapeutics' average media sentiment score of 0.68 beat VistaGen Therapeutics' score of 0.48 indicating that Tenax Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VistaGen Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is TENX or VTGN more profitable? Tenax Therapeutics has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -6,777.08%. Tenax Therapeutics' return on equity of -31.34% beat VistaGen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tenax TherapeuticsN/A -31.34% -30.39% VistaGen Therapeutics -6,777.08%-74.06%-64.10% Do institutionals & insiders hold more shares of TENX or VTGN? 1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are owned by institutional investors. 3.1% of Tenax Therapeutics shares are owned by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, TENX or VTGN? Tenax Therapeutics has higher earnings, but lower revenue than VistaGen Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenax TherapeuticsN/AN/A-$17.60M-$0.92-6.97VistaGen Therapeutics$490K190.34-$51.42M-$1.78-1.71 Which has more volatility & risk, TENX or VTGN? Tenax Therapeutics has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. SummaryTenax Therapeutics beats VistaGen Therapeutics on 13 of the 16 factors compared between the two stocks. Get Tenax Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENX vs. The Competition Export to ExcelMetricTenax TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.25M$3.14B$5.81B$10.34BDividend YieldN/A2.37%5.86%4.62%P/E Ratio-6.9721.3676.9327.00Price / SalesN/A251.55450.1588.91Price / CashN/A45.4837.2260.63Price / Book0.249.6913.836.37Net Income-$17.60M-$52.92M$3.29B$271.46M7 Day Performance4.40%1.44%0.93%2.35%1 Month Performance6.66%6.03%5.31%7.78%1 Year Performance77.56%12.89%84.25%32.27% Tenax Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENXTenax Therapeutics2.3919 of 5 stars$6.41+2.6%$18.00+180.8%+65.8%$29.25MN/A-6.979High Trading VolumeVTGNVistaGen Therapeutics0.9307 of 5 stars$3.48-2.0%N/A-6.5%$108.92M$490K-1.9640Short Interest ↑TCRXTScan Therapeutics2.6253 of 5 stars$1.88-1.6%$7.80+314.9%-70.6%$108.39M$2.82M-1.72100Positive NewsONCYOncolytics Biotech2.3739 of 5 stars$1.28+20.8%$5.00+290.6%+40.8%$106.38MN/A-4.7430News CoverageAnalyst RevisionGap UpHigh Trading VolumeHLVXHilleVax1.5139 of 5 stars$2.09-0.5%$2.00-4.3%+16.0%$105.30MN/A-1.4620News CoverageShort Interest ↑COYACoya Therapeutics2.7557 of 5 stars$6.37+1.6%$16.50+159.0%-11.9%$104.87M$423.45K-5.146News CoverageAnalyst ForecastSRZNSurrozen2.1137 of 5 stars$11.36-6.9%$38.50+238.9%+40.7%$104.56M$10.65M-0.7980SAVACassava Sciences1.8007 of 5 stars$2.14-0.9%$2.00-6.5%-93.4%$104.35MN/A-0.8430ADAGAdagene3.3216 of 5 stars$2.39+8.6%$7.00+192.9%-12.4%$103.69M$100K0.00260Positive NewsShort Interest ↓Gap UpKALAKALA BIO4.3531 of 5 stars$14.48-0.5%$17.25+19.1%+200.2%$102.16M$3.89M-2.1330News CoverageAnalyst ForecastATOSAtossa Genetics1.5341 of 5 stars$0.81+2.4%$6.17+664.1%-42.8%$101.79MN/A-3.518News Coverage Related Companies and Tools Related Companies VistaGen Therapeutics Alternatives TScan Therapeutics Alternatives Oncolytics Biotech Alternatives HilleVax Alternatives Coya Therapeutics Alternatives Surrozen Alternatives Cassava Sciences Alternatives Adagene Alternatives KALA BIO Alternatives Atossa Genetics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENX) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenax Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TENX Stock Alerts